Life Science Investing Summit Therapeutics to Host ESMO Data Update & Third Quarter Earnings Call on October 20, 2025
Life Science Investing HARMONi-6, Featuring Ivonescimab Combined with Chemotherapy vs. Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in China, to be Showcased in Presidential Symposium at ESMO 2025
Life Science Investing Longer-Term Follow-Up of Western Patients Showed Improving, Favorable Trend in Overall Survival in Global Phase III HARMONi Clinical Trial for Ivonescimab Plus Chemotherapy in 2L+ EGFRm NSCLC
pharmaceutical investing Summit Awarded Additional $12 Million by BARDA for Phase 3 Development Programme of Ridinilazole for the Treatment of C. difficile Infection
Apple unveils new 14-inch MacBook Pro powered by the M5 chip, delivering the next big leap in AI for the Mac